Genomic Vision Provides Strategy Update

Regulatory News:

Genomic Vision (FR0011799907 – GV, – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to provide a business update on its refocused strategy.

Under new leadership, Genomic Vision is committed to delivering high-quality genomic solutions that play a critical role in improving quality control and bioproduction standards, supporting the development of advanced cell and gene therapies (CGTs). The Company is focused on leveraging its unique Molecular Combing Technology (MCT), that offers precise visualization and measurement of individual DNA molecules, to capitalize on the rapidly growing demand for highly accurate, fast, and accessible solutions for genome characterization of advanced therapies at scale. Key areas of focus include:

• Bioproduction - a complete characterization of genetic material in line with quality control requirements for biomaterial production.
• Cell and gene therapy - safety and quality control, and AI-powered cell line performance prediction to ensure compliance, de-risk development, shorten timelines, reduce costs and optimize outcomes.
• Drug discovery - early identification to evaluate the efficacy of oncology and chemotherapy compounds targeting DNA replication or repair pathways.

The Company has made encouraging progress towards its strategic objectives to date, including the development of a next-generation MCT platform in partnership with Cambridge Consultants. This new hardware, which relies on miniaturized integrated fluidic technology, will deliver a more seamless user experience, reduce MCT analysis turnaround times, automate sample handling and significantly improve Genomic Vision’s assessing capability. The Company expects to launch its next-generation technology platform by the end of 2024, facilitating the transition to a mixed business model with recurring revenue based on products, consumables and partnership agreements.

Harnessing the power of Artificial Intelligence (AI), Genomic Vision is enhancing the precision and scalability of genomic analysis, accelerating its operations by 30% and reducing error margins by 50%. FiberSmart is a data analysis software that uses advanced AI algorithms for the analysis of Replication Combing Assays (RCA), an application of MCT. Launched in February 2023, FiberSmart was successfully tested and validated by AstraZeneca (LSE/STO/Nasdaq: AZN), and the Fritz Lipmann Institute, Germany, and offers notable enhancements in speed and accuracy of data analysis over existing software solutions while also delivering 95% accurate AI-powered predictive analytics.